This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Ralph Lauren (RL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ralph Lauren (RL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RLNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NVCRNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MLTXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ENTANegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ARCTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ATRCNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Dream Finders Homes (DFH) Could Surge 26.83%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 26.8% upside potential for Dream Finders Homes (DFH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
DFHPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Ivanhoe Electric (IE)? Wall Street Analysts Think 105.88%
by Zacks Equity Research
The consensus price target hints at a 105.9% upside potential for Ivanhoe Electric (IE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
IEPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NTLANegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 78.84% Upside in QuinStreet (QNST): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 78.8% upside potential for QuinStreet (QNST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
QNSTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PSTVPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Urban Outfitters (URBN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Urban Outfitters (URBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
URBNNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Lowe's (LOW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Lowe's (LOW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOWNegative Net Change HDNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Target (TGT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Target (TGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TGTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Domo (DOMO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Domo (DOMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DOMONegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Zoom Communications (ZM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zoom (ZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZMNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 161.5% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
QURENegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Xperi (XPER) Could Rally 118.82%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at an 118.8% upside potential for Xperi (XPER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
XPERNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 83.9% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZYMENegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 40.5% Upside in Sangoma Technologies Corporation (SANG): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 40.5% upside potential for Sangoma Technologies Corporation (SANG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SANGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 195.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TRVIPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EWTXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Crexendo (CXDO) Could Surge 42.86%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Crexendo (CXDO) points to a 42.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CXDONegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Pagaya Technologies Ltd. (PGY) Could Rally 51.67%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Pagaya Technologies Ltd. (PGY) points to a 51.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PGYNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Janus International Group (JBI) Could Rally 27.06%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Janus International Group (JBI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
JBINegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate